| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3027 | Human LILRB1-CHO-K1 Stable Cell Line | 2 vials | $4950 | Order |
| Catalog Number | C3027 |
|---|---|
| Cell Line Name | Human LILRB1-CHO-K1 Stable Cell Line |
| Accession Number | Q8NHL6 (Full-length cDNA) |
| Host Cell | Adherent CHO-K1 |
| Quantity | Two vials of frozen cells (1x106 per vial) |
| Culture Medium | DMEM with 10% FBS, 4 ug/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen upon receipt |
| Product Datasheet: | Download PDF |
Detection of human LILRB1 expression on CHO-K1 cells using PE-anti human LILRB1 antibody (BioLegend #333708)
Leukocyte immunoglobulin-like receptor B1 (LILRB1), also known as leukocyte immunoglobulin-like receptor 8 (LIR-8), is a type I transmembrane protein belonging to the immunoglobulin superfamily. It is expressed on the surface of various immune cells, including monocytes, macrophages, dendritic cells, and natural killer (NK) cells. LILRB1 is characterized by its extracellular domain, which contains four immunoglobulin-like domains and two cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Through its ITIMs, LILRB1 recruits tyrosine phosphases to inhibit the activity of immune cells like NK cells, monocytes, macrophages, and T and B cells. LILRB1 has been shown to play a role in various biological processes, including phagocytosis, cytokine production, and immune tolerance. In cancer, LILRB1 expression is increased leading to tumor progression, immune evasion and metastasis. Specifically, LILRB1 binds to tumor cells expressing beta 2 microglobulin complexed with MHC class I, allowing an escape from T cell recognition. Given its natural inhibitory function, LILRB1 is immunosuppressive and indirectly tumor supporting. Therefore studies suggest that targeting LILRB1 or disrupting the MHC class I-LILRB1 signaling axis can stop tumor progression in cancer, making LILRB1 a focus as a therapeutic target for cancer treatment.
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 19(1):76-84. 2017
Deng M, Chen H, Liu X, Huang R, He Y, Yoo B, Xie J, John S, Zhang N, An Z, Zhang CC. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib Ther. 4(1):16-33. 2021.